Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Concordance in judgments among c-erbB-2 (HER2/neu) overexpression detectedby two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma
Autore:
Tsuda, H; Tani, Y; Hasegawa, T; Fukutomi, T;
Indirizzi:
Natl Canc Ctr, Res Inst & Hosp, Div Pathol, Tokyo 104, Japan Natl Canc Ctr Tokyo Japan 104 Inst & Hosp, Div Pathol, Tokyo 104, Japan DAKO Japan Co, DAKO Lab, Kyoto, Japan DAKO Japan Co Kyoto JapanDAKO Japan Co, DAKO Lab, Kyoto, Japan
Titolo Testata:
PATHOLOGY INTERNATIONAL
fascicolo: 1, volume: 51, anno: 2001,
pagine: 26 - 32
SICI:
1320-5463(200101)51:1<26:CIJAC(>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
GROWTH-FACTOR RECEPTOR; LONG-TERM SURVIVAL; PROTEIN OVEREXPRESSION; CANCER PATIENTS; NEU ONCOGENE; AGREEMENT; CHEMOTHERAPY; EXPRESSION; EFFICACY; ANTIBODY;
Keywords:
breast cancer; c-erbB-2 (HER2/neu); gene amplification; HercepTest(TM); immunohistochemistry; interobserver agreement;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Tsuda, H Natl Def Med Coll, Dept Pathol 2, 3-2 Namiki, Tokorozawa, Saitama3598513,Japan Natl Def Med Coll 3-2 Namiki Tokorozawa Saitama Japan 3598513 pan
Citazione:
H. Tsuda et al., "Concordance in judgments among c-erbB-2 (HER2/neu) overexpression detectedby two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma", PATHOL INT, 51(1), 2001, pp. 26-32

Abstract

We compared the c-erbB-2 protein overexpression status detected by the HercepTest(TM) (DAKO A/S, Grostrup, Denmark) with another conventional immunohistochemistry system using an anti-c-erbB-2 rabbit polyclonal antibody (Nichirei Co., Tokyo, Japan) and with the c-erbB-2 gene amplification status detected by Southern blot hybridization in 101 surgically resected breast carcinomas. According to the criteria for overexpression, recommended by the manufacturer, c-erbB-2 overexpression by HercepTest(TM) was detected in 24 cancers (24%), comprising six score-2 tumors and 18 score-3 tumors. The level of agreement in judgment of the HercepTest(TM), among three independent observers, was excellent (kappa = 0.845). C-erbB-2 overexpression by Nichirei's antibody and c-erbB-2 gene amplification were detected in 21% and 16% of cases, respectively, and their concordance with HercepTest(TM) scores of 2-3 was 89% and 90%, respectively. In the score-3 cases by Hercep Test(TM) only, the concordance rates with overexpression by Nichirei's immunohistochemistry and with gene amplification were slightly higher, 94% and 93%, respectively. Score-2 cases by HercepTest(TM) were mostly judged as negative overexpression by Nichirei's antibody and as no amplification by Southern blot hybridization. The present results showed that HercepTest(TM) score-3 detected c-erbB-2 overexpression almost optimally as well as the conventional methods and the score-3 breast carcinomas had clinical and biological implications. Further examination would be necessary to decide the significance of breast cancers of HercepTest(TM) score 2.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/09/20 alle ore 06:37:39